Moderna Inc. (MRNA) announced that the U.S. Food and Drug Administration has approved its respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease (LRTD) caused by RSV in adults aged 18-59 who are at increased risk.
The approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.